Latest Articles

Publication Date
FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis - FinancialContent

FinancialContent - Sur180 Therapeutics and Nura Health Announce Strategic Partnership to Advance Precision Diagnostics and Next-Generation Non-Hormonal Treatments for Endometriosis FinancialContent

Published: March 18, 2026, 10 a.m.
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update The Manila Times

Published: March 16, 2026, 12:15 p.m.
Exosome-Enriched Hub Gene Networks Identify Diagnostic Biomarkers and Repurposable Therapeutic Targets in Endometriosis.

Endometriosis is a heterogeneous chronic inflammatory disorder associated with substantial diagnostic delay and limited therapeutic options, highlighting the need of robust non-invasive biomarkers and actionable molecular targets to complement existing …

Published: March 11, 2026, midnight
TCF21 promotes epithelial-to-mesenchymal transition and cytoskeleton reorganization in uterine development and endometriosis.

Endometriosis is a common gynecological disease associated with pelvic pain and infertility. Despite several existing theories, the etiology and molecular mechanisms of endometriosis remain to be investigated. Here we report …

Published: March 5, 2026, midnight
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com

Jefferies reiterates Acrivon Therapeutics stock rating on trial data Investing.com

Published: March 2, 2026, 9:32 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World

Published: March 2, 2026, 6:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com

Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress Investing.com

Published: Feb. 27, 2026, 2:18 p.m.
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference The Manila Times

Published: Feb. 24, 2026, 1:18 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!